doi:10.1371/journal.pone.0033944 Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ et al (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
The 100 mg quantity in this listing is much larger than the 5 to 20 mg typical elsewhere in the catalog, and the reason is straightforward: the published work uses this compound at micromolar to millimolar working concentrations rather than the nanomolar concentrations at which receptor agonists are studied, and formulation and matrix-stability work consumes material quickly
Do I need lab tests for sleep problems
Regular check-ups can assess the effectiveness of the treatment and make necessary modifications
Exp Neurol 2015;263:177-89